Evaluating anticoagulation duration for pulmonary embolism in ICU patients
Evaluation of the Duration of Obtaining Curative Anticoagulation in Patients With Clinically Significant Pulmonary Embolism in an Intensive Care Unit
This study is testing how long ICU patients with serious pulmonary embolism should be treated with blood thinners to see how well it helps them recover.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06912009 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with clinically significant pulmonary embolism who are hospitalized in the intensive care unit. It aims to evaluate the duration of curative anticoagulation treatment, specifically using unfractionated heparin, and its effectiveness in managing this condition. The study will monitor the initiation of anticoagulation therapy and its outcomes based on various clinical parameters. Data will be collected from patients diagnosed with pulmonary embolism and treated with curative doses of anticoagulants.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are hospitalized in the intensive care unit with a confirmed diagnosis of pulmonary embolism.
Not a fit: Patients who have not received curative anticoagulation or those with pulmonary embolism diagnosed prior to ICU admission may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management and treatment protocols for patients with pulmonary embolism in intensive care settings.
How similar studies have performed: Other studies have shown success in evaluating anticoagulation strategies for pulmonary embolism, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years old) * Hospitalized in the intensive care unit of Hautepierre Hospital (Strasbourg University Hospitals UF 6250) between January 1, 2014, and December 31, 2023 * With a diagnosis of pulmonary embolism confirmed by a thoracic CT angiogram, a thoracoabdominopelvic CT scan, or a lung scan * Having received anticoagulation with curative-dose unfractionated heparin Exclusion Criteria: * Subjects who have expressed objection to the reuse of their data for scientific research purposes. - Patients diagnosed with pulmonary embolism prior to admission to the intensive care unit and for whom we cannot precisely determine the start date of anticoagulation (precision estimated to the nearest hour). * Pulmonary embolism not confirmed by contrast imaging (CT angiography) * Patients who have not received curative anticoagulation (contraindication) * Patients already receiving curative anticoagulation with UFH at the time of diagnosis * Patients with low-risk pulmonary embolism defined by an sPESI score of 0 * Subject under court protection, guardianship, or curatorship
Where this trial is running
Strasbourg
- Service de Réanimation Médicale - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Vincent CASTELAIN, MD, PhD
- Email: vincent.castelain@chru-strasbourg.fr
- Phone: 33.3.88.12.79.15
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.